388 related articles for article (PubMed ID: 16849664)
1. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease.
Machado RF; Anthi A; Steinberg MH; Bonds D; Sachdev V; Kato GJ; Taveira-DaSilva AM; Ballas SK; Blackwelder W; Xu X; Hunter L; Barton B; Waclawiw M; Castro O; Gladwin MT;
JAMA; 2006 Jul; 296(3):310-8. PubMed ID: 16849664
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary hypertension in patients with sickle cell/beta thalassemia: incidence and correlation with serum N-terminal pro-brain natriuretic peptide concentrations.
Voskaridou E; Tsetsos G; Tsoutsias A; Spyropoulou E; Christoulas D; Terpos E
Haematologica; 2007 Jun; 92(6):738-43. PubMed ID: 17550845
[TBL] [Abstract][Full Text] [Related]
3. NT-pro brain natriuretic peptide levels and the risk of death in the cooperative study of sickle cell disease.
Machado RF; Hildesheim M; Mendelsohn L; Remaley AT; Kato GJ; Gladwin MT
Br J Haematol; 2011 Aug; 154(4):512-20. PubMed ID: 21689089
[TBL] [Abstract][Full Text] [Related]
4. N-terminal natriuretic peptide and ventilation-perfusion lung scan in sickle cell disease and thalassemia patients with pulmonary hypertension.
Mokhtar GM; Adly AA; El Alfy MS; Tawfik LM; Khairy AT
Hemoglobin; 2010; 34(1):78-94. PubMed ID: 20113292
[TBL] [Abstract][Full Text] [Related]
5. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.
Fijalkowska A; Kurzyna M; Torbicki A; Szewczyk G; Florczyk M; Pruszczyk P; Szturmowicz M
Chest; 2006 May; 129(5):1313-21. PubMed ID: 16685024
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of the plasma N-terminal pro-brain natriuretic peptide level on all-cause death and major cardiovascular events in a community-based population.
Zhu Q; Xiao W; Bai Y; Ye P; Luo L; Gao P; Wu H; Bai J
Clin Interv Aging; 2016; 11():245-53. PubMed ID: 27013868
[TBL] [Abstract][Full Text] [Related]
7. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for death in 632 patients with sickle cell disease in the United States and United Kingdom.
Gladwin MT; Barst RJ; Gibbs JS; Hildesheim M; Sachdev V; Nouraie M; Hassell KL; Little JA; Schraufnagel DE; Krishnamurti L; Novelli E; Girgis RE; Morris CR; Berman Rosenzweig E; Badesch DB; Lanzkron S; Castro OL; Taylor JG; Goldsmith JC; Kato GJ; Gordeuk VR; Machado RF;
PLoS One; 2014; 9(7):e99489. PubMed ID: 24988120
[TBL] [Abstract][Full Text] [Related]
9. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech TM; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TAJ; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):106-113. PubMed ID: 27908301
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.
Gladwin MT; Sachdev V; Jison ML; Shizukuda Y; Plehn JF; Minter K; Brown B; Coles WA; Nichols JS; Ernst I; Hunter LA; Blackwelder WC; Schechter AN; Rodgers GP; Castro O; Ognibene FP
N Engl J Med; 2004 Feb; 350(9):886-95. PubMed ID: 14985486
[TBL] [Abstract][Full Text] [Related]
11. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.
Kistorp C; Raymond I; Pedersen F; Gustafsson F; Faber J; Hildebrandt P
JAMA; 2005 Apr; 293(13):1609-16. PubMed ID: 15811980
[TBL] [Abstract][Full Text] [Related]
12. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.
Klings ES; Machado RF; Barst RJ; Morris CR; Mubarak KK; Gordeuk VR; Kato GJ; Ataga KI; Gibbs JS; Castro O; Rosenzweig EB; Sood N; Hsu L; Wilson KC; Telen MJ; Decastro LM; Krishnamurti L; Steinberg MH; Badesch DB; Gladwin MT;
Am J Respir Crit Care Med; 2014 Mar; 189(6):727-40. PubMed ID: 24628312
[TBL] [Abstract][Full Text] [Related]
13. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
[TBL] [Abstract][Full Text] [Related]
14. NT-proBNP levels and cardiopulmonary function in children with sickle cell disease.
Feld L; Fiorino EK; Aygun B; Appiah-Kubi A; Mitchell EC; Jackson S; Mehran R; Fishbein J; Santiago MT
Pediatr Pulmonol; 2021 Feb; 56(2):495-501. PubMed ID: 33151019
[TBL] [Abstract][Full Text] [Related]
15. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis.
Allanore Y; Borderie D; Avouac J; Zerkak D; Meune C; Hachulla E; Mouthon L; Guillevin L; Meyer O; Ekindjian OG; Weber S; Kahan A
Arthritis Rheum; 2008 Jan; 58(1):284-91. PubMed ID: 18163505
[TBL] [Abstract][Full Text] [Related]
16. N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension.
Leuchte HH; El Nounou M; Tuerpe JC; Hartmann B; Baumgartner RA; Vogeser M; Muehling O; Behr J
Chest; 2007 Feb; 131(2):402-9. PubMed ID: 17296640
[TBL] [Abstract][Full Text] [Related]
17. C-reactive protein and NT-proBNP as surrogate markers for pulmonary hypertension in Gaucher disease.
Elstein D; Nir A; Klutstein M; Rudensky B; Zimran A
Blood Cells Mol Dis; 2005; 34(3):201-5. PubMed ID: 15885602
[TBL] [Abstract][Full Text] [Related]
18. Serial Measurements of N-Terminal Pro-B-Type Natriuretic Peptide Serum Level for Monitoring Pulmonary Arterial Hypertension in Children.
Said F; Haarman MG; Roofthooft MTR; Hillege HL; Ploegstra MJ; Berger RMF
J Pediatr; 2020 May; 220():139-145. PubMed ID: 32113658
[TBL] [Abstract][Full Text] [Related]
19. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
[TBL] [Abstract][Full Text] [Related]
20. B-type natriuretic peptide as a parameter for pulmonary hypertension in children. A systematic review.
Ten Kate CA; Tibboel D; Kraemer US
Eur J Pediatr; 2015 Oct; 174(10):1267-75. PubMed ID: 26298682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
